Wang Gang, Duan Jianfeng, Cao Ke, Gao Tao, Jiang Anqi, Xu Yun, Zhu Zhanghua, Yu Wenkui
Department of Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, Jiangsu, China.
The State Key Laboratory of Pharmaceutical Biotechnology, Nanjing 210008, Jiangsu, China. Corresponding author: Yu Wenkui, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024 Aug;36(8):841-847. doi: 10.3760/cma.j.cn121430-20231121-01003.
To investigate the protective effects and mechanisms of targeted inhibition of type 3 deiodinase (Dio3) on skeletal muscle mitochondria in sepsis.
(1) In vivo experiments: adeno-associated virus (AAV) was employed to specifically target Dio3 expression in the anterior tibial muscle of rats, and a septic rat model was generated using cecal ligation and puncture (CLP). The male Sprague-Dawley (SD) rats were divided into shNC+Sham group, shD3+Sham group, shNC+CLP group, and shD3+CLP group by random number table method, with 8 rats in each group. After CLP modeling, tibial samples were collected and Western blotting analysis was conducted to assess the protein levels of Dio3, peroxisome proliferator-activated receptor-γ coactivator-1α (PGC1α), and silence-regulatory protein 1 (SIRT1). Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) was utilized to examine mRNA expression of genes including thyroid hormone receptors (THRα, THRβ), monocarboxylate transporter 10 (MCT10), mitochondrial DNA (mtDNA), and PGC1α. Transmission electron microscopy was employed to investigate mitochondrial morphology. (2) In vitro experiments: involved culturing C2C12 myoblasts, interfering with Dio3 expression using lentivirus, and constructing an endotoxin cell model by treating cells with lipopolysaccharide (LPS). C2C12 cells were divided into shNC group, shD3 group, shNC+LPS group, and shD3+LPS group. Immunofluorescence colocalization analysis was performed to determine the intracellular distribution of PGC1α. Co-immunoprecipitation assay coupled with Western blotting was carried out to evaluate the acetylation level of PGC1α.
(1) In vivo experiments: compared with the shNC+Sham group, the expression of Dio3 protein in skeletal muscle of the shNC+CLP group was significantly increased (Dio3/β-Tubulin: 3.32±0.70 vs. 1.00±0.49, P < 0.05), however, there was no significant difference in the shD3+Sham group. Dio3 expression in the shD3+CLP group was markedly reduced relative to the shNC+CLP group (Dio3/β-Tubulin: 1.42±0.54 vs. 3.32±0.70, P < 0.05). Compared with the shNC+CLP group, the expression of T3-regulated genes in the shD3+CLP group were restored [THRα mRNA (2): 0.67±0.05 vs. 0.33±0.01, THRβ mRNA (2): 0.94±0.05 vs. 0.67±0.02, MCT10 mRNA (2): 0.65±0.03 vs. 0.57±0.02, all P < 0.05]. Morphology analysis by electron microscopy suggested prominent mitochondrial damage in the skeletal muscle of the shNC+CLP group, while the shD3+CLP group exhibited a marked improvement. Compared with the shNC+Sham group, the shNC+CLP group significantly reduced the number of mitochondria (cells/HP: 10.375±1.375 vs. 13.750±2.063, P < 0.05), while the shD3+CLP group significantly increased the number of mitochondria compared to the shNC+CLP group (cells/HP: 11.250±2.063 vs. 10.375±1.375, P < 0.05). The expression of mtDNA in shNC+CLP group was markedly reduced compared with shNC+Sham group (copies: 0.842±0.035 vs. 1.002±0.064, P < 0.05). Although no difference was detected in the mtDNA expression between shD3+CLP group and shNC+CLP group, but significant increase was found when compared with the shD3+Sham group (copies: 0.758±0.035 vs. 0.474±0.050, P < 0.05). In the shD3+CLP group, PGC1α expression was significantly improved at both transcriptional and protein levels relative to the shNC+CLP group [PGC1α mRNA (2): 1.49±0.13 vs. 0.68±0.06, PGC1α/β-Tubulin: 0.76±0.02 vs. 0.62±0.04, both P < 0.05]. (2) In vitro experiments: post-24-hour LPS treatment of C2C12 cells, the cellular localization of PGC1α became diffuse; interference with Dio3 expression promoted PGC1α translocation to the perinuclear region and nucleus. Moreover, the acetylated PGC1α level in the shD3+LPS group was significantly lower than that in the shNC+LPS group (acetylated PGC1α/β-Tubulin: 0.59±0.01 vs. 1.24±0.01, P < 0.05), while the expression of the deacetylating agent SIRT1 was substantially elevated following Dio3 inhibition (SIRT1/β-Tubulin: 1.04±0.04 vs. 0.58±0.03, P < 0.05). When SIRT1 activity was inhibited by using EX527, PGC1α protein expression was notably decreased compared to the shD3+LPS group (PGC1α/β-Tubulin: 0.92±0.03 vs. 1.58±0.03, P < 0.05).
Inhibition of Dio3 in skeletal muscle reduced the acetylation of PGC1α through activating SIRT1, facilitating nuclear translocation of PGC1α, thereby offering protection against sepsis-induced skeletal muscle mitochondrial damage.
探讨靶向抑制3型脱碘酶(Dio3)对脓毒症骨骼肌线粒体的保护作用及机制。
(1)体内实验:采用腺相关病毒(AAV)特异性靶向大鼠胫前肌中Dio3的表达,通过盲肠结扎穿刺(CLP)建立脓毒症大鼠模型。将雄性Sprague-Dawley(SD)大鼠按随机数字表法分为shNC+假手术组、shD3+假手术组、shNC+CLP组和shD3+CLP组,每组8只。CLP建模后,采集胫骨样本,进行蛋白质免疫印迹分析以评估Dio3、过氧化物酶体增殖物激活受体γ共激活因子1α(PGC1α)和沉默调节蛋白1(SIRT1)的蛋白水平。利用实时荧光定量聚合酶链反应(RT-qPCR)检测甲状腺激素受体(THRα、THRβ)、单羧酸转运体10(MCT10)、线粒体DNA(mtDNA)和PGC1α等基因的mRNA表达。采用透射电子显微镜观察线粒体形态。(2)体外实验:培养C2C12成肌细胞,用慢病毒干扰Dio3表达,并用脂多糖(LPS)处理细胞构建内毒素细胞模型。C2C12细胞分为shNC组、shD3组、shNC+LPS组和shD3+LPS组。进行免疫荧光共定位分析以确定PGC1α的细胞内分布。采用免疫共沉淀结合蛋白质免疫印迹法评估PGC1α的乙酰化水平。
(1)体内实验:与shNC+假手术组相比,shNC+CLP组骨骼肌中Dio3蛋白表达显著增加(Dio3/β-微管蛋白:3.32±0.70 vs. 1.00±0.49,P<0.05),而shD3+假手术组无显著差异。shD3+CLP组中Dio3表达相对于shNC+CLP组明显降低(Dio3/β-微管蛋白:1.42±0.54 vs. 3.32±0.70,P<0.05)。与shNC+CLP组相比,shD3+CLP组中T3调节基因的表达得到恢复[THRα mRNA(2):0.67±0.05 vs. 0.33±0.01,THRβ mRNA(2):0.94±0.05 vs. 0.67±0.02,MCT10 mRNA(2):0.65±0.03 vs. 0.57±0.02,均P<0.05]。电子显微镜形态分析表明,shNC+CLP组骨骼肌中线粒体损伤明显,而shD3+CLP组有明显改善。与shNC+假手术组相比,shNC+CLP组线粒体数量显著减少(细胞/高倍视野:10.375±1.375 vs. 13.750±2.063,P<0.05),而shD3+CLP组与shNC+CLP组相比线粒体数量显著增加(细胞/高倍视野:11.250±2.063 vs. 10.375±1.375,P<0.05)。shNC+CLP组中mtDNA表达与shNC+假手术组相比明显降低(拷贝数:0.842±0.035 vs. 1.002±0.064,P<0.05)。虽然shD3+CLP组与shNC+CLP组之间mtDNA表达未检测到差异,但与shD3+假手术组相比显著增加(拷贝数:0.758±0.035 vs. 0.474±0.050,P<0.05)。在shD3+CLP组中,相对于shNC+CLP组,PGC1α在转录和蛋白水平均显著改善[PGC1α mRNA(2):1.49±0.13 vs. 0.68±0.06,PGC1α/β-微管蛋白:0.76±0.02 vs. 0.62±0.04,均P<0.05]。(2)体外实验:C2C12细胞经LPS处理24小时后,PGC1α的细胞定位变得弥散;干扰Dio3表达促进PGC1α转位至核周区域和细胞核。此外,shD3+LPS组中乙酰化PGC1α水平显著低于shNC+LPS组(乙酰化PGC1α/β-微管蛋白:0.59±0.01 vs. 1.24±0.01,P<0.05),而抑制Dio3后去乙酰化剂SIRT1的表达显著升高(SIRT1/β-微管蛋白:1.04±0.04 vs. 0.58±0.03,P<0.05)。当用EX527抑制SIRT1活性时,与shD3+LPS组相比,PGC1α蛋白表达显著降低(PGC1α/β-微管蛋白:0.92±0.03 vs. 1.58±0.03,P<0.05)。
抑制骨骼肌中的Dio3可通过激活SIRT1减少PGC1α的乙酰化,促进PGC1α核转位,从而对脓毒症诱导的骨骼肌线粒体损伤起到保护作用。